At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 458 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Semaglutide and Dulaglutide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 458 participants across 34 sites.
Detailed Summary
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartJan 2017
Primary CompletionJul 2018
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartJan 10, 2017
Primary CompletionJul 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.5 years ago
Interventions
Semaglutidedrug
Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
Dulaglutidedrug
Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).